Shares of Endologix, Inc. (NASDAQ:ELGX) have been assigned an average rating of “Hold” from the thirteen research firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and eleven have assigned a hold recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $6.50.

Several brokerages have issued reports on ELGX. ValuEngine cut Endologix from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. BidaskClub cut Endologix from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Canaccord Genuity reaffirmed a “hold” rating on shares of Endologix in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 target price on Endologix and gave the company a “hold” rating in a research report on Thursday, August 3rd. Finally, Stifel Nicolaus set a $6.00 target price on Endologix and gave the company a “hold” rating in a research report on Wednesday, August 2nd.

Several institutional investors have recently bought and sold shares of ELGX. Teachers Advisors LLC boosted its position in shares of Endologix by 3.9% in the 4th quarter. Teachers Advisors LLC now owns 130,313 shares of the medical instruments supplier’s stock worth $745,000 after purchasing an additional 4,851 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Endologix by 34.5% in the 1st quarter. Nationwide Fund Advisors now owns 258,787 shares of the medical instruments supplier’s stock worth $1,874,000 after purchasing an additional 66,340 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Endologix by 7.6% in the 1st quarter. Wells Fargo & Company MN now owns 157,990 shares of the medical instruments supplier’s stock worth $1,144,000 after purchasing an additional 11,188 shares in the last quarter. Great West Life Assurance Co. Can boosted its position in shares of Endologix by 6,604.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 448,025 shares of the medical instruments supplier’s stock worth $3,249,000 after purchasing an additional 441,342 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Endologix by 30.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 89,748 shares of the medical instruments supplier’s stock worth $650,000 after purchasing an additional 20,685 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Endologix, Inc. (ELGX) Given Consensus Rating of “Hold” by Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/16/endologix-inc-elgx-given-consensus-rating-of-hold-by-brokerages.html.

Shares of Endologix (ELGX) opened at 4.50 on Friday. The company’s 50 day moving average price is $4.39 and its 200 day moving average price is $5.55. Endologix has a 52-week low of $4.08 and a 52-week high of $13.30. The company’s market capitalization is $375.45 million.

Endologix (NASDAQ:ELGX) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.08. The company had revenue of $48.60 million for the quarter, compared to the consensus estimate of $47.58 million. Endologix had a negative return on equity of 46.32% and a negative net margin of 40.77%. Endologix’s quarterly revenue was down 4.6% on a year-over-year basis. During the same period last year, the business posted ($0.20) EPS. On average, analysts predict that Endologix will post ($0.62) EPS for the current year.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.